期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ERCC-1和RRM-1在NSCLC中的表达及其病理临床意义 被引量：3

Expression of ERCC-1 and RRM-1 and its relationship with clinical pathological characteristics in non-small cell lung cancer
暂未订购
导出
摘要 目的检测核苷酸切除修复(NER)系统的ERCC-1和RRM-1在非小细胞肺癌(NSCLC)组织中的表达并分析其表达的病理临床意义,为探索NSCLC的有关发生机制及术后辅助化疗提供有用的实验依据。方法应用免疫组织化学二步法检测128例NSCLC组织中ERCC-1和RRM-1的表达,以10例支气管扩张症肺组织作为对照。结果1.ERCC-1在NSCLC组织中的总体阳性表达率为44.53%(57/128),在对照组肺组织气道上皮的阳性表达率为100%(10/10),ERCC-1在NSCLC组织和对照组的阳性率差异有统计学意义(P<0.05);RRM-1在NSCLC组织中的总体阳性表达率为75%(96/128),在对照组肺组织气道上皮不表达,RRM-1在NSCLC组织和对照组的阳性率差异有统计学意义(P<0.05)。2.ERCC-1的表达与NSCLC患者的年龄、组织学类型及分化程度存在相关性(P<0.05);RRM-1的表达与NSCLC患者的年龄存在相关性(P<0.05)。NSCLC组织中ERCC-1与RRM-1的表达呈正相关(P<0.01)。结论ERCC-1表达降低或缺失可能与NSCLC发生有关;NSCLC组织中存在着ERCC-1与RRM-1的差异表达,提示不同个体的NSCLC其生物学行为可能不同,因此检测NSCLC组织中NER系统的表达情况对选择NSCLC的个性化辅助化疗及估计患者的预后有指导意义。 Objective To investigate the expression of ERCC-1 and RRM-1 proteins of the nucleotide excision repair（NER） system in patients with non-small cell lung cancer（NSCLC） and to analyze their correlations with the clinicopathological characteristics,providing a helpful experimental evidence for exploring NSCLC pathogenesis and resistance to chemotherapeutic drugs.Methods Immunohistochemical methods were used to investigate the expression of ERCC-1 and RRM-1 proteins in 128 cases of histopathologically defined NSCLC and 10 cases of bronchiectasis.Results 1.The positive expression rate of ERCC-1 and RRM-1 in NSCLC was 44.53%（57/128） and 75%（96/128）,respectively.The different positive rates between NSCLC and control lung tissues had statistical significance.2.The expression of ERCC-1 was related to age,histological type and tumor grade,but the expression of RRM-1 was related to age in patients with NSCLC.The relationship between ERCC-1 and RRM-1 was positive.Conclusion The reduction or lack of ERCC-1 expression may be significant in the pathogenesis of NSCLC.The expressions of ERCC-1 and RRM-1 were different in some individuals of NSCLC,indicating that the biological behavior may be different in them.It may be of great significance to detect the expression of the NER system in NSCLC for choosing the best adjuvant chemotherapy and estimating individual patient＇s prognosis.
作者 李明显 夏传生 李娜萍
机构地区 华中科技大学同济医学院附属同济医院病理研究所 中国人民解放军第
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2011年第2期135-139,共5页 Chinese Journal of Histochemistry and Cytochemistry
关键词 错配切除交叉互补修复酶1 核糖核苷酸还原酶M1 非小细胞肺癌 ERCC-1 RRM-1 NSCLC
分类号 R365 [医药卫生—病理学]
  • 相关文献

参考文献11

  • 1Jaclyn Flanigan,Hari Deshpande,Scott Gettinger.Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer.Biologics:Targets & Therapy,2010,4:237-243.
  • 2曾敬,饶慧兰,张惠忠,侯景辉,吴惠茜,赵美卿.细胞骨架蛋白tubulin α、β在不同级别胶质瘤中的表达及其与预后的相关性[J].实用肿瘤杂志,2005,20(6):497-499. 被引量：6
  • 3殷柳,齐瑾,刘基巍.ERCC1、RRM1及BRCA1在非小细胞肺癌中表达及其临床意义[J].现代肿瘤医学,2009,17(4):788-791. 被引量：6
  • 4Junichi Shimizu,Yoshitsugu Horio,Hirotaka Osada,et al.mRNA expression of RRM1,ERCC1 and ERCC2 is not associated with chemo-sensitivity to cisplatin,carboplatin and gemcitabine in human lung cancer cell lines.Respirology,2008,13:510-517.
  • 5Chiun Hsua,Sung-Hsin Kuo,Fu-Chang Hud,et al.Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial.Lung Cancer,2008,62:334-343.
  • 6A.C.Vilmar,E.Santoni-Rugiu.ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.Annals of Oncology,2010,21:1817-1824.
  • 7HyunWoo Lee,Yong-Won Choi,Jae Ho Han.Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.Lung Cancer,2009,65:377-382.
  • 8Koichi Azuma,Tetsuro Sasada,Akihiko Kawahara,et al.Expression of ERCC1 and class III -tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.Cancer Chemother Pharmacol,2009,64:565-573.
  • 9Olaussen KA,Dunant A,Fouret P,et al.DNA repair by ERCC1 in non-small lung cancer and cisplatin-based adjuvant chemotherapy.N Engl J Med,2006,355(10):983-991.
  • 10Jae Jin Leea,Chi Hoon Maengb,Seon Kyung Baek,et al.The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer(NSCLC).2010,70(2):205-210.

二级参考文献47

  • 1林莉,刘晓晴,宋三泰.DNA损伤修复与铂类耐药研究进展[J].中国肿瘤,2006,15(1):29-31. 被引量：29
  • 2Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging[ J ]. Chest, 1997,111 : 1718 - 1723.
  • 3Arriagada R, Bergman B, Dunant A, et al. Cisplatin based adjuvant chemotherapy in patients with completely resected non - small - cell lung cancer[ J ]. N Engl J Med,2004,350 : 351 - 360.
  • 4Rosell R, Cecere F, Santarpia M,et al. Predicting the outcome of chemotherapy for lung cancer[ J ]. Curr Opin Pharmacol, 2006,6 : 323 -331.
  • 5Zhou W, Liu G, Park S, et al. Gene smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer[ J]. Cancer Epidermal Biomarkers Prey, 2005,14 (2) :491 - 496.
  • 6Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non- small- cell lung cancer[ J]. Clin Cancer Res,2002 ,8 :2286 - 2291.
  • 7RoseU R, Lord RV, Taron M, et al. DNA repair and cisplatin resistance in non - small - cell lung cancer [ J ]. Lung Cancer , 2002, 38:217 - 227.
  • 8Zhou W, Gurubhagavatnla S, Liu G, et al. Excision repair cresscomplementation group 1 polymorphism predicts overall survival in advanced non - small cell lung cancer patients treated with platinum - based chemotherapy[ J]. Clin Cancer Res,2004,10 ( 15 ) :4939- 4943.
  • 9RoseU R, Gandara D, Cobo M, et al. Customizing cisplatin based on quantitative excision repair cross - complementing 1 mRNA expression: A phase Ⅲ randomized trial in non - small cell lung cancer [ C ]. The 31 st Congress of the European Society of Medical Oncology, Turkey: Instanbul,2003.
  • 10Olaussen KA, Ariane D, Fouret P, et al. DNA repair by ERCC1 in non- small - cell lung cancer and cisplatin - based adjuvant chemotherapy[J]. N Engl J Med, 2006,355:983 -991.

共引文献10

同被引文献26

  • 1刘联,王秀问,黎莉,张昕,张文东,于学军.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].癌症,2006,25(8):990-994. 被引量：93
  • 2陈芹,周彩存,张颉.ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J].肿瘤,2007,27(9):719-722. 被引量：57
  • 3Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J Clin, 2011,61(2) : 69-90. DOI: 10.3322/eaac. 20107.
  • 4Jordheim LP, Sere P, Tredan O, et al. The ribonueleotide reduetase large subunit (RRM1) as a predictive factor in patients with cancer [J]. Lancet Oncal, 2011, 12(7) :.693-702. DOI: I0.1016/Sl470- 2045 ( 10 ) 70244 -8.
  • 5Furuta E, Okuda H, Kobayashi A, et al. Metabolic genes in. cancer: their roles in tumor progression and clinical implications[ J]. Bioehim Biophys Acta, 2010, 1805(2) : 141-152. DOI: 10. 1016/j. bbean. 2010.01. 005.
  • 6Wang QC, Liu XY, Zhou JC, et al. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer[J]. PLoS One, 2013, 8(7) : e70191. DOI: 10. 1371/journal. pone. 0070191.
  • 7Tanwar PS, Kaneko-Tarui T, Lee HJ, et al. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression [ J ]. Carcinogenesis, 2013, 34 (4) : 893-901. DOI: 10. 1093/carcin/bgs405.
  • 8Mulholland DJ, Kobayashi N, Ruscetti M, et al. Pten loss and RAS/ MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells[ J]. Cancer Res, 2012, 72 (7) : 1878-1889. DOI: 10. 1158/0008-5472. CAN-11-3132.
  • 9Lee JJ, Maeng CH, Baek SK, et al. The expression of fibonucleotide reductase regulatory subunit M1 ( RRM1 ) protein is a predictor of shorter survival to gemcitabine-based chemo- therapy in advanced non-small cell hmg cancer (NSCLC) [ J ]. Lung Cancer, 2010, 70(2) : 205-210. DOI: 10. 1016/j. lungcan. 2010. 02. 005.
  • 10Uchibori K, Kasamatsu A, Sunaga M, et al. Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcino- ma cell lines[J]. Int J Oncol, 2012, 40(4): 1005-1010. DOI: 10. 3892/ijo. 2011. 1300.

引证文献3

二级引证文献5

中国组织化学与细胞化学杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部